IntelGenx Technologies Corp.

Greetings. Welcome to the Intel GenX first quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Stephen Kilmer. You may begin.

Good afternoon, and thank you for joining us on today's call. With me on the line are Dr. Horst Zerbe, Intelligent X's chairman and former CEO, Dwight Gorham, Intelligent X's newly appointed CEO, Andre Godin, our president and CFO, Dr. David Kadeko, the company's head of corporate development and strategic alliances, Dr. Frank Piatrantonio, our director of clinical research, and Tommy Kemi, our senior vice president and general counsel. Before we begin, I would like to remind you that all amounts mentioned today are in U.S. dollars unless otherwise mentioned, and today's call may contain forward-looking information that represents our expectations as of today and accordingly are subject to change. We do not undertake any obligation to update any forward-looking statements except as may be required by U.S. and Canadian securities laws. A number of assumptions were made by us in preparing these forward-looking statements, which are subject to risks and results may differ materially. Details on these risks and assumptions can be found in our filings with the U.S. and Canadian Securities Commissions. I would now like to turn the call over to Dr. Zervais. Of course.

Thank you, Steve. Good afternoon, everyone, and thank you for joining us for the Intertenix first quarter 2023 conference call. On today's call, I will provide a corporate update and discuss the progress we have made on our key pipeline projects. Then André will review our financial results. Following that, we will open up the line for your questions. Before launching into an update, I would like to take this opportunity to welcome our newly appointed CEO, Dwight Gorham, to our team and to his inaugural Intergenics Index call. About a year ago, I informed the Board of Directors of my intent to retire as CEO of the company. The board subsequently appointed a succession committee chaired by Bernard Boudreau, which, after thorough search that was conducted with the help of the Montreal-based executive search firm Heidrich & Struggles, recommended that the board appoint Dwight Gorham as the new CEO of the company. On March 13th, the board accepted my resignation and unanimously appointed Dwight Warren as the new CEO, effective upon my resignation. I will continue to serve on the board and remain available to help the new CEO during the transition. Dwight is exceptionally well qualified to lead intergenics through and beyond its transformation from an R&D company to a successful commercial manufacturing operation. Dwight is an engineer by training. Most recently, Dwight served as president and CEO of Pillar 5 Pharma, a pharmaceutical contract manufacturing organization with a specialty in sterile ophthalmic products. Before joining Pillar 5 in 2015, he served as senior vice president and general manager of global operations of Pharma Science. Prior to that, he held a variety of senior roles, including President and CEO at AccuCaps Industries, a leading North American supplier of soft gelatin capsules, a variety of management assignments at the Borough's Welcome Facility in Montreal, President of GlaxoPharma, a Montreal-based CMO and supplier of parenteral and lyophilization products, General Manager of Baker Cummings and Director of Operations, at the Canadian arm of Glaxo, which is now GSK. During each of these assignments, he managed to significantly improve the financial performance of the company or the unit he was responsible for. While he's still just getting up to speed, Dwight has agreed to join us today on the call, and he will be available to participate in the Q&A session following our introductory remarks.